



上海源叶生物科技有限公司  
 Shanghai yuanye Bio-Technology Co., Ltd  
 电话: 021-61312973 传真: 021-55068248  
 网址: www.shyuanye.com  
 邮箱: shyysw@sina.com

产品名称: 阿伐斯汀  
 产品别名: **Acrivastine; BW825C**

生物活性:					
<b>Description</b>	Acrivastine (BW825C) is a short acting histamine 1 receptor antagonist for the treatment of allergic rhinitis.				
<b>In Vivo</b>	Acrivastine (usually 8mg three times daily) is an effective and well tolerated antihistamine in the treatment of chronic urticaria and allergic rhinitis. Acrivastine is more effective than placebo and similar in efficacy to clemastine or terfenadine in the treatment of seasonal allergic rhinitis. In the treatment of dermatoses in which histamine has a pathogenetic role, the efficacy of acrivastine is superior to that of placebo and similar to that of usual dosages of clemastine, hydroxyzine, chlorpheniramine, cyproheptadine or terfenadine. Acrivastine causes less drowsiness than clemastine, the incidence of adverse effects being indistinguishable from that with placebo or terfenadine[1]. Both 4 mg and 8 mg acrivastine alleviate the symptoms of seasonal allergic rhinitis with significant improvements in the symptom scores for sneezing, running nose and the calculated overall score. In addition, 8 mg acrivastine reduces the symptom scores for watery eyes and itchy throat. Acrivastine is both well tolerated and effective in the treatment of seasonal allergic rhinitis[2].				
<b>Solvent&amp;Solubility</b>	<b>In Vitro:</b> DMSO : 10.45 mg/mL (29.99 mM; Need ultrasonic)				
		Solvent Mass Concentration	1 mg	5 mg	10 mg
	<b>Preparing</b>	1 mM	2.8699 mL	14.3497 mL	28.6993 mL
	<b>Stock Solutions</b>	5 mM	0.5740 mL	2.8699 mL	5.7399 mL
		10 mM	0.2870 mL	1.4350 mL	2.8699 mL
	*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。				
<b>References</b>	[1]. Brogden RN, et al. Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Drugs. 1991 Jun;41(6):927-40. [2]. Gibbs TG, et al. Acrivastine in two doses compared with placebo in a multicentre, parallel group study for the treatment of seasonal allergic rhinitis. Br J Clin Pract. 1989 Jan;43(1):11-4.				